The pricing decisions behind recently-launched authorized generics offer an indicator of how manufacturers would respond to implementation of the HHS proposed rule to eliminate rebates in Medicare Part D and Medicaid managed care plans, according to pharmacy benefit experts speaking at a National Business Group on Health conference April 11.
Prices might be lower, though that’s not a given. Executives from major manufacturers have told members of Congress they would...






